The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 17, 2015
Filed:
Sep. 26, 2012
Thomas Raymond Caferro, Abington, MA (US);
Young Shin Cho, Cambridge, MA (US);
Abran Q. Costales, El Cerrito, CA (US);
Huangshu Lei, Chongqing, CN;
Francois Lenoir, Waltham, MA (US);
Julian Roy Levell, Arlington, MA (US);
Gang Liu, Waltham, MA (US);
Mark G. Palermo, Rindge, NH (US);
Keith Bruce Pfister, San Ramon, CA (US);
Martin Sendzik, San Mateo, CA (US);
Cynthia Shafer, El Sobrante, CA (US);
Michael David Shultz, Lexington, MA (US);
Troy Smith, Nashua, NH (US);
James Clifford Sutton, Pleasanton, CA (US);
Bakary-barry Toure, Weston, MA (US);
Fan Yang, West Roxbury, MA (US);
Qian Zhao, El Cerrito, CA (US);
Thomas Raymond Caferro, Abington, MA (US);
Young Shin Cho, Cambridge, MA (US);
Abran Q. Costales, El Cerrito, CA (US);
Huangshu Lei, Chongqing, CN;
Francois Lenoir, Waltham, MA (US);
Julian Roy Levell, Arlington, MA (US);
Gang Liu, Waltham, MA (US);
Mark G. Palermo, Rindge, NH (US);
Keith Bruce Pfister, San Ramon, CA (US);
Martin Sendzik, San Mateo, CA (US);
Cynthia Shafer, El Sobrante, CA (US);
Michael David Shultz, Lexington, MA (US);
Troy Smith, Nashua, NH (US);
James Clifford Sutton, Pleasanton, CA (US);
Bakary-Barry Toure, Weston, MA (US);
Fan Yang, West Roxbury, MA (US);
Qian Zhao, El Cerrito, CA (US);
Novartis AG, Basel, CH;
Abstract
The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R-Rare defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.